Pharmaco-metabolomics and metabolomics: A new tool in precision medicine?

Precision medicine aims to integrate individual patient characteristics into therapeutic decisions. Metabolomics and pharmaco-metabolomics enable direct exploration of the biological phenotype through comprehensive analysis of the metabolites present in an organism. These approaches provide an integrative perspective that considers the interactions among the genome, environment, microbiota, and lifestyle, paving the way for better prediction of treatment efficacy and the prevention of adverse events. However, their implementation faces technical, analytical, organizational, and regulatory hurdles. The Giens 2025 Workshops brought together academic, institutional, and industrial experts to identify the ambitions of pharmaco-metabolomics and the obstacles to its development, ultimately proposing key recommendations. These recommendations focus on standardizing practices, enhancing professional training, improving data interoperability, and increasing the accessibility of analytical tools. Thus, pharmaco-metabolomics is positioned as a significant lever for integrating the biological phenotype into personalized medicine by 2030.